[HTML][HTML] Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)
Background: Lung cancer is the number one cause of mortality among all types of cancer
worldwide. Its treatment landscape has shifted from the classic chemotherapy alone to …
worldwide. Its treatment landscape has shifted from the classic chemotherapy alone to …
Docetaxel liposomes for lung targeted delivery: development and evaluation
Y Liu, Z Zhao, S Zhu, Y Cheng, J Liu, T Ye… - Pharmaceutical …, 2023 - Taylor & Francis
Docetaxel (DTX) is an artificial semi-synthetic second-generation taxane anti-tumor drug,
which is suitable for the treatment of various cancers such as lung cancer. The route of …
which is suitable for the treatment of various cancers such as lung cancer. The route of …
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III …
LG Paz-Ares, O Juan-Vidal, GS Mountzios… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE The open-label, phase III EVOKE-01 study evaluated sacituzumab govitecan
(SG) versus standard-of-care docetaxel in metastatic non–small cell lung cancer (mNSCLC) …
(SG) versus standard-of-care docetaxel in metastatic non–small cell lung cancer (mNSCLC) …